Abstract
We used baseline data from a sample of African-American women living with HIV who were recruited to participate in a stigma-reduction intervention in Chicago and Birmingham (2013–2015) to (1) evaluate the relationship between HIV-related stigma and viral suppression, and (2) assess the role of depression and nonadherence to antiretroviral therapy (ART) as mediators. Data from women were included in this secondary analysis if they were on ART, had viral load data collected within 8-weeks of study entry and had complete covariate data. We used logistic regression to estimate the total effect of HIV-related stigma (14-item Stigma Scale for Chronic Illness) on viral suppression (< 200 copies/mL), and serial mediation analysis to estimate indirect effects mediated by depressive symptoms (8-item Patient Health Questionnaire) and ART nonadherence (number of days with missed doses). Among 100 women who met study inclusion criteria, 95% reported some level of HIV-related stigma. In adjusted models, higher levels of HIV-related stigma were associated with lower odds of being virally suppressed (AOR = 0.93, 95% CI = 0.89–0.98). In mediation analysis, indirect effects through depression and ART nonadherence were not significant. Findings suggest that HIV-related stigma is common among African-American women living with HIV, and those who experience higher levels of stigma are less likely to be virally suppressed. However, the mechanisms remain unclear.
Similar content being viewed by others
References
CDC. Fact sheet: HIV among African Americans 2017. Updated February 2017. https://www.cdc.gov/nchhstp/newsroom/docs/factsheets/cdc-hiv-aa-508.pdf.
Torian LV, Wiewel EW, Liu KL, Sackoff JE, Frieden TR. Risk factors for delayed initiation of medical care after diagnosis of human immunodeficiency virus. Arch Intern Med. 2008;168(11):1181–7.
Novak RM, Hart RL, Chmiel JS, Brooks JT, Buchacz K. Disparities in initiation of combination antiretroviral treatment and in virologic suppression among patients in the HIV Outpatient Study, 2000–2013. J Acquir Immune Defic Syndr. 2015;70(1):23–32.
CDC. Fact sheet: HIV in the United States: the stages of care: Centers for Disease Control and Prevention; 2014 [CDC Fact Sheet]. http://www.cdc.gov/nchhstp/newsroom/docs/HIV-Stages-of-Care-Factsheet-508.pdf.
Beer L, Mattson CL, Bradley H, Skarbinski J. Understanding cross-sectional racial, ethnic, and gender disparities in antiretroviral use and viral suppression among HIV patients in the United States. Medicine. 2016;95(13):e3171.
Ribaudo HJ, Smith KY, Robbins GK, Flexner C, Haubrich R, Chen Y, et al. Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis. Clin Dis. 2013;57(11):1607–17.
Beer L, Bradley H, Mattson CL, Johnson CH, Hoots B, Shouse RL. Trends in racial and ethnic disparities in antiretroviral therapy prescription and viral suppression in the United States, 2009–2013. J Acquir Immune Defic Syndr. 2016;73(4):446–53.
Lesko CR, Cole SR, Miller WC, Westreich D, Eron JJ, Adimora AA, et al. Ten-year survival by race/ethnicity and sex among treated, HIV-infected adults in the United States. Clin Dis. 2015;60(11):1700–7.
Lemly DC, Shepherd BE, Hulgan T, Rebeiro P, Stinnette S, Blackwell RB, et al. Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis. 2009;199(7):991–8.
Murphy S, Xu J, Kochanek K. Deaths: final data for 2010. May 8, 2013. Contract No. 4; 2013.
Singh GK, Azuine RE, Siahpush M. Widening socioeconomic, racial, and geographic disparities in HIV/AIDS mortality in the United States, 1987–2011. Adv Prev Med. 2013;2013:657961.
Lillie-Blanton M, Stone VE, Snow Jones A, Levi J, Golub ET, Cohen MH, et al. Association of race, substance abuse, and health insurance coverage with use of highly active antiretroviral therapy among HIV-infected women, 2005. Am J Public Health. 2010;100(8):1493–9.
Cohen MH, Cook JA, Grey D, Young M, Hanau LH, Tien P, et al. Medically eligible women who do not use HAART: the importance of abuse, drug use, and race. Am J Public Health. 2004;94(7):1147–51.
Losina E, Schackman BR, Sadownik SN, Gebo KA, Walensky RP, Chiosi JJ, et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis. 2009;49(10):1570–8.
Meditz AL, MaWhinney S, Allshouse A, Feser W, Markowitz M, Little S, et al. Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis. 2011;203(4):442–51.
Herek GM, Mitnick L, Burris S, Chesney M, Devine P, Fullilove MT, et al. Workshop report: AIDS and stigma: a conceptual framework and research agenda. AIDS Public Policy J. 1998;13(1):36–47.
Buseh AG, Stevens PE. Constrained but not determined by stigma: resistance by African American women living with HIV. Women Health. 2006;44(3):1–18.
Sanicki A, Mannell J. HIV-positive African-American women’s perspectives on engaging communities in the response to HIV/AIDS in Washington, D.C. AIDS Care. 2015;27(10):1213–9.
Muturi N, An S. HIV/AIDS stigma and religiosity among African American women. J Health Commun. 2010;15(4):388–401.
Fletcher F, Ingram LA, Kerr J, Buchberg M, Bogdan-Lovis L, Philpott-Jones S. “She told them, oh that bitch got AIDS”: experiences of multilevel HIV/AIDS-related stigma among African American women living with HIV/AIDS in the South. AIDS Patient Care STDs. 2016;30(7):349–56.
McDoom MM, Bokhour B, Sullivan M, Drainoni ML. How older black women perceive the effects of stigma and social support on engagement in HIV care. AIDS Patient Care STDs. 2015;29(2):95–101.
Grodensky CA, Golin CE, Jones C, Mamo M, Dennis AC, Abernethy MG, et al. “I should know better”: the roles of relationships, spirituality, disclosure, stigma, and shame for older women living with HIV seeking support in the South. J Assoc Nurses AIDS Care. 2015;26(1):12–23.
Clark HJ, Lindner G, Armistead L, Austin BJ. Stigma, disclosure, and psychological functioning among HIV-infected and non-infected African-American women. Women Health. 2003;38(4):57–71.
Wingood GM, Diclemente RJ, Mikhail I, McCree DH, Davies SL, Hardin JW, et al. HIV discrimination and the health of women living with HIV. Women Health. 2007;46(2–3):99–112.
Vyavaharkar M, Moneyham L, Corwin S, Saunders R, Annang L, Tavakoli A. Relationships between stigma, social support, and depression in HIV-infected African American women living in the rural Southeastern United States. J Assoc Nurses AIDS Care. 2010;21(2):144–52.
Rao D, Kekwaletswe TC, Hosek S, Martinez J, Rodriguez F. Stigma and social barriers to medication adherence with urban youth living with HIV. AIDS care. 2007;19(1):28–33.
Rintamaki LS, Davis TC, Skripkauskas S, Bennett CL, Wolf MS. Social stigma concerns and HIV medication adherence. AIDS Patient Care STDs. 2006;20(5):359–68.
Edwards LV. Perceived social support and HIV/AIDS medication adherence among African American women. Qual Health Res. 2006;16(5):679–91.
Carr RL, Gramling LF. Stigma: a health barrier for women with HIV/AIDS. J Assoc Nurses AIDS Care. 2004;15(5):30–9.
Rao D, Feldman BJ, Fredericksen RJ, Crane PK, Simoni JM, Kitahata MM, et al. A structural equation model of HIV-related stigma, depressive symptoms, and medication adherence. AIDS Behav. 2012;16(3):711–6.
Mitzel LD, Vanable PA, Brown JL, Bostwick RA, Sweeney SM, Carey MP. Depressive symptoms mediate the effect of HIV-related stigmatization on medication adherence among HIV-infected men who have sex with men. AIDS Behav. 2015;19(8):1454–9.
Turan B, Smith W, Cohen MH, Wilson TE, Adimora AA, Merenstein D, et al. Mechanisms for the negative effects of internalized HIV-related stigma on antiretroviral therapy adherence in women: the mediating roles of social isolation and depression. J Acquir Immune Defic Syndr. 2016;72(2):198–205.
Turan B, Hatcher AM, Weiser SD, Johnson MO, Rice WS, Turan JM. Framing mechanisms linking HIV-related stigma, adherence to treatment, and health outcomes. Am J Public Health. 2017;107(6):863–9.
Rao D, Kemp CG, Huh D, Nevin PE, Turan J, Cohn SE, et al. Stigma reduction among African American women with HIV: UNITY Health Study. J Acquir Immune Defic Syndr. 2018;78(3):269–75.
Lalama CM, Jennings C, Johnson VA, Coombs RW, McKinnon JE, Bremer JW, et al. Comparison of three different FDA-approved plasma HIV-1 RNA assay platforms confirms the virologic failure endpoint of 200 copies per milliliter despite improved assay sensitivity. J Clin Microbiol. 2015;53(8):2659–66.
U.S. Department of Health and Human Services. U.S. Department of Health and Human Services (HHS) Performance Indicators; 2016. Updated 5/11/2016. https://hab.hrsa.gov/stateprofiles/HHS-Indicators.aspx.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; 2016.
Rao D, Choi SW, Victorson D, Bode R, Peterman A, Heinemann A, et al. Measuring stigma across neurological conditions: the development of the stigma scale for chronic illness (SSCI). Qual Life Res. 2009;18(5):585–95.
Rao D, Molina Y, Lambert N, Cohn SE. Assessing stigma among African Americans living with HIV. Stigma Health. 2016;1(3):146–55.
Kroenke K, Strine TW, Spitzer RL, Williams JB, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009;114(1–3):163–73.
Center for Quality Assessment and Improvement in Mental Health. The patient health questionnaire (PHQ-9) overview; 1999.
Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10(3):227–45.
Lu M, Safren SA, Skolnik PR, Rogers WH, Coady W, Hardy H, et al. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav. 2008;12(1):86–94.
Galvan FH, Davis EM, Banks D, Bing EG. HIV stigma and social support among African Americans. AIDS Patient Care STDs. 2008;22(5):423–36.
Hahn JA, Samet JH. Alcohol and HIV disease progression: weighing the evidence. Curr HIV/AIDS Rep. 2010;7(4):226–33.
Sullivan LE, Fiellin DA, O’Connor PG. The prevalence and impact of alcohol problems in major depression: a systematic review. Am J Med. 2005;118(4):330–41.
Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr. 2009;52(2):180–202.
Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998;158(16):1789–95.
Rubinsky AD, Dawson DA, Williams EC, Kivlahan DR, Bradley KA. AUDIT-C scores as a scaled marker of mean daily drinking, alcohol use disorder severity, and probability of alcohol dependence in a U.S. general population sample of drinkers. Alcohol Clin Exp Res. 2013;37(8):1380–90.
Chavez LJ, Williams EC, Lapham G, Bradley KA. Association between alcohol screening scores and alcohol-related risks among female veterans affairs patients. J Stud Alcohol Drugs. 2012;73(3):391–400.
Bryson CL, Au DH, Sun H, Williams EC, Kivlahan DR, Bradley KA. Alcohol screening scores and medication nonadherence. Ann Intern Med. 2008;149(11):795–804.
Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res. 2007;31(7):1208–17.
Bradley KA, Rubinsky AD, Lapham GT, Berger D, Bryson C, Achtmeyer C, et al. Predictive validity of clinical AUDIT-C alcohol screening scores and changes in scores for three objective alcohol-related outcomes in a Veterans Affairs population. Addiction (Abingdon, England). 2016;111(11):1975–84.
StataCorp. Stata Statistical Software: Release 13. College Station: StataCorp LP; 2013.
IBM Corp. SPSS Statistics for Windows, version 25. Armonk: IBM Corp; 2017.
Hayes AF. Introduction to mediation, moderation, and conditional process analysis: a regression-based approach. New York: Guilford Press; 2013.
Bradley KA, Bush KR, Epler AJ, Dobie DJ, Davis TM, Sporleder JL, et al. Two brief alcohol-screening tests From the Alcohol Use Disorders Identification Test (AUDIT): validation in a female Veterans Affairs patient population. Arch Intern Med. 2003;163(7):821–9.
Rao D, Desmond M, Andrasik M, Rasberry T, Lambert N, Cohn SE, et al. Feasibility, acceptability, and preliminary efficacy of the unity workshop: an internalized stigma reduction intervention for African American women living with HIV. AIDS Patient Care STDs. 2012;26(10):614–20.
Sumari-de Boer IM, Sprangers MA, Prins JM, Nieuwkerk PT. HIV stigma and depressive symptoms are related to adherence and virological response to antiretroviral treatment among immigrant and indigenous HIV infected patients. AIDS Behav. 2012;16(6):1681–9.
Baugher AR, Beer L, Fagan JL, Mattson CL, Freedman M, Skarbinski J, et al. Prevalence of internalized HIV-related stigma among HIV-infected adults in care, United States, 2011–2013. AIDS Behav. 2017;21(9):2600–8.
Parker R, Aggleton P. HIV and AIDS-related stigma and discrimination: a conceptual framework and implications for action. Soc Sci Med. 2003;57(1):13–24.
Logie CH, James L, Tharao W, Loutfy MR. HIV, gender, race, sexual orientation, and sex work: a qualitative study of intersectional stigma experienced by HIV-positive women in Ontario, Canada. PLoS Med. 2011;8(11):e1001124.
Rao D, Andrasik MP, Lipira L. HIV stigma among Black women in the United States: intersectionality, support, resilience. Am J Public Health. 2018;108(4):446–8.
Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS. 2001;15(16):2109–17.
Katz IT, Ryu AE, Onuegbu AG, Psaros C, Weiser SD, Bangsberg DR, et al. Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. J Int AIDS Soc. 2013;16(3 Suppl 2):18640.
Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr. 2011;58(2):181–7.
Shadish WR, Cook TD, Campbell DT. Experimental and quasi-experimental designs for generalized causal inference. Belmont: Wadsworth Cengage Learning; 2002.
Leserman J. HIV disease progression: depression, stress, and possible mechanisms. Biol Psychiat. 2003;54(3):295–306.
Helms BC, Turan JM, Atkins G, Kempf MC, Clay OJ, Raper JL, et al. Interpersonal mechanisms contributing to the association between HIV-related internalized stigma and medication adherence. AIDS Behav. 2016;21(1):238–47.
Walcott M, Kempf MC, Merlin JS, Turan JM. Structural community factors and sub-optimal engagement in HIV care among low-income women in the Deep South of the USA. Culture Health Sex. 2015;18(6):682–94.
Kaiser Family Foundation. Fact sheet: Black Americans and HIV/AIDS; 2017. http://kff.org/hivaids/fact-sheet/black-americans-and-hiv-aids/.
Bhandari M, Lochner H, Tornetta P 3rd. Effect of continuous versus dichotomous outcome variables on study power when sample sizes of orthopaedic randomized trials are small. Arch Orthop Trauma Surg. 2002;122(2):96–8.
Acknowledgements
This study was made possible by funding from NIMH grant R01-MH98675 (PI: Rao) with additional support from Ms. Lipira’s AHRQ Health Services Training Award (T32 HS013853-13) and Dr. Williams’s VA Health Services Research & Development Career Development Award (CDA 12-276). The authors would also like to extend a special thank you to the women who participated in the Unity Study.
Funding
This study was made possible by funding from NIMH grant R01-MH98675 (PI: Rao) with additional support from Ms. Lipira’s AHRQ Health Services Training Award (T32 HS013853-13) and Dr. Williams’s VA Health Services Research & Development Career Development Award (CDA 12-276).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflicts of interest.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed Consent
Informed consent was obtained from all individual participants included in the study.
Appendices
Appendix 1: Baseline Characteristics of African-American Women Living with HIV Who Participated in a Trial of an HIV-Related Stigma-Reduction Intervention, Comparing Those Who Had Viral Loads Collected Within 8-Weeks of Study Entry (Primary Sample) to Those Who Had Viral Loads Collected Within 24-Weeks of Study Entry (Sensitivity Sample)
Primary sample (8-week viral load) (N = 100) | Sensitivity sample (24-week viral load) (N = 184) | |||
---|---|---|---|---|
Median/N | IQR/ % | Median/N | IQR/ % | |
Site | ||||
NU | 26 | 26% | 374 | 19% |
CORE | 31 | 31% | 65 | 35% |
UAB | 43 | 43% | 85 | 46% |
Age (years) | 45 years | 38–53 | 46 years | 39–54 |
Time living with HIV (years) | 14 years | 9–20 | 14 years | 8–20 |
Education | ||||
Less than HS | 39 | 39% | 68 | 37% |
HS or equivalent | 18 | 18% | 41 | 22% |
College | 32 | 32% | 59 | 32% |
More than college | 11 | 11% | 16 | 9% |
Alcohol use severity (AUDIT-C score) | ||||
0 | 46 | 46% | 81 | 44% |
1–2 | 30 | 30% | 63 | 34% |
3–7 | 21 | 21% | 36 | 20% |
8–12 | 3 | 3% | 4 | 2% |
HIV-related stigma (SSCI) | 31 | 23–41 | 30 | 22–41 |
Depressive symptom severity (PHQ-8) | 7 | 3–13 | 6 | 2–12 |
ART nonadherence (out of 30 days) | 1 | 0–2 | 1 | 0–2 |
Viral suppression | ||||
Yes | 79 | 79% | 156 | 78% |
No | 21 | 21% | 44 | 22% |
Appendix 2: Sensitivity Analysis Comparing Direct And Indirect Effects of HIV-Related Stigma on Viral Suppression Among Two Samples of African-American Women Living with HIV Enrolled in the Unity Study, Differing by Viral Load Collection Period
Primary sample (8-week viral load) (N = 100) | Sensitivity sample (24-week viral load) (N = 184) | |||
---|---|---|---|---|
β | 95% CI | β | 95% CI | |
Primary model a | ||||
Total effect (difference in log-odds) | − 0.069 | − 0.117 to − 0.021 | − 0.052 | − 0.084 to − 0.020 |
Direct effect | − 0.085 | − 0.145 to − 0.025 | − 0.043 | − 0.082 to − 0.004 |
Indirect effects | ||||
Stigma > depression > nonadherence > viral suppression | − 0.006 | − 0.045 to 0.029 | − 0.003 | − 0.010 to 0.002 |
Stigma > depression > viral suppression | 0.010 | − 0.046 to 0.054 | 0.010 | − 0.037 to 0.014 |
Stigma > nonadherence > viral suppression | 0.002 | − 0.087 to 0.051 | 0.001 | − 0.012 to 0.010 |
Secondary model b | ||||
Total effect (difference in log-odds) | − 0.096 | − 0.016 to − 0.032 | − 0.056 | − 0.089 to − 0.022 |
Direct effect | − 0.238 | − 0.385 to − 0.091 | − 0.052 | − 0.092 to − 0.011 |
Indirect effects | ||||
Stigma > depression > nonadherence > viral suppression | − 0.010 | − 0.072 to 0.054 | − 0.002 | − 0.011 to 0.003 |
Stigma > depression > viral suppression | 0.064 | − 0.140 to 0.206 | 0.006 | − 0.034 to 0.021 |
Stigma > nonadherence > viral suppression | 0.009 | − 0.105 to 0.107` | 0.001 | − 0.012 to 0.011 |
Rights and permissions
About this article
Cite this article
Lipira, L., Williams, E.C., Huh, D. et al. HIV-Related Stigma and Viral Suppression Among African-American Women: Exploring the Mediating Roles of Depression and ART Nonadherence. AIDS Behav 23, 2025–2036 (2019). https://doi.org/10.1007/s10461-018-2301-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10461-018-2301-4